Safety and Efficacy of Bevacizumab Plus Standard-of-Care Treatment Beyond Disease Progression in Patients With Advanced Non–Small Cell Lung Cancer: The AvaALL Randomized Clinical Trial

IMPORTANCE: Bevacizumab treatment beyond progression has been investigated in breast and metastatic colorectal cancers. Avastin in All Lines Lung (AvaALL) is the first randomized phase 3 study of bevacizumab across multiple lines of treatment beyond progression in non–small cell lung cancer (NSCLC)....

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:JAMA Oncol
Glavni autori: Gridelli, Cesare, de Castro Carpeno, Javier, Dingemans, Anne-Marie C., Griesinger, Frank, Grossi, Francesco, Langer, Corey, Ohe, Yuichiro, Syrigos, Konstantinos, Thatcher, Nick, Das-Gupta, Ashis, Truman, Matt, Donica, Margarita, Smoljanovic, Vlatka, Bennouna, Jaafar
Format: Artigo
Jezik:Inglês
Izdano: American Medical Association 2018
Teme:
Brief Report
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6440713/
https://ncbi.nlm.nih.gov/pubmed/30177994
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2018.3486
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items